Does Capricor Therapeutics Inc (NASDAQ:CAPR) presents a BIG investment opportunity?

Stocks of Capricor Therapeutics Inc (NASDAQ:CAPR) traded higher last session on Wall Street, up 8.26% to $11.94.

CAPR stock price is now 0.03 away from the 50-day moving average and May 13 AMC away from the 200-day moving average. The market capitalization of the company currently stands at $377.55M.

With the price target of $31, Roth Capital recently initiated with Buy rating for Capricor Therapeutics Inc (NASDAQ: CAPR). On October 21, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $35, while ‘Oppenheimer’ rates the stock as ‘Outperform’

In other news, Nippon Shinyaku Co Ltd, 10% Owner bought 2,798,507 shares of the company’s stock on Sep 20 ’24. The stock was bought for $14,999,998 at an average price of $5.36. Upon completion of the transaction, the 10% Owner now directly owns 7,090,351 shares in the company, valued at $84.66 million. A total of 12.16% of the company’s stock is owned by insiders.

During the past 12 months, Capricor Therapeutics Inc has had a low of $3.52 and a high of $23.40. The fifty day moving average price for CAPR is $10.825 and a two-hundred day moving average price translates $13.37315 for the stock.

The latest earnings results from Capricor Therapeutics Inc (NASDAQ: CAPR) was released for 2025-03-31. The net profit margin was -317.13% and return on equity was -75.39% for CAPR.

Related Posts

Fosters Research
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.